Source comparison
Comparison with Other Growth Hormone Secretagogues
The GH secretagogue landscape includes multiple peptide families, each with distinct receptor profiles and side effect signatures. Ipamorelin peptide occupies a specific niche defined by what it doesn't do as much as what it does. GHRP-6 was one of the earlies
This comparison does not assign a generated winner or score.
- The GH secretagogue landscape includes multiple peptide families, each with distinct receptor profiles and side effect signatures. Ipamorelin peptide occupies a specific niche defined by what it doesn't do as much as what it does.
- GHRP-6 was one of the earliest growth hormone-releasing peptides to demonstrate clinical efficacy. It stimulates substantial GH release, but it also activates ghrelin receptors in the hypothalamus that trigger hunger signaling—subjects in early trials reported significant appetite increases within 20–30 minutes of administration. GHRP-6 also elevates prolactin and cortisol modestly, which introduces variables that complicate metabolic studies.
- GHRP-2 improved on GHRP-6 by reducing the appetite effect slightly, but cortisol and prolactin elevation persisted. Both compounds remain useful in research contexts where those secondary effects are acceptable or even desired, but they lack the precision ipamorelin offers.
- Hexarelin represents the most potent GH secretagogue by peak amplitude—it produces GH pulses 50–70% larger than ipamorelin at equivalent molar doses. The tradeoff is desensitization: repeated hexarelin administration downregulates GHS-R1a receptor density within 7–14 days, a phenomenon that does not occur with ipamorelin even after weeks of daily dosing. For long-duration studies, that difference is decisive.
- Sermorelin takes a different approach entirely—it's a growth hormone-releasing hormone (GHRH) analog, not a ghrelin receptor agonist. Sermorelin stimulates GH release by binding to GHRH receptors on pituitary somatotrophs, which means it works synergistically with ipamorelin rather than redundantly. The combination—often referred to as a GHRH/GHRP stack—produces GH pulses larger than either compound alone, a result of complementary receptor pathways converging on the same secretory machinery.
- Here's how the major secretagogues compare on key research parameters:
- | Peptide | GH Release Potency | Cortisol Elevation | Prolactin Elevation | Appetite Stimulation | Receptor Desensitization | Half-Life ||—|—|—|—|—|—|| Ipamorelin | Moderate (dose-dependent) | None | None | Minimal | None observed | ~2 hours || GHRP-6 | High | Modest | Modest | Significant | Minimal | ~2–3 hours || GHRP-2 | High | Modest | Modest | Moderate | Minimal | ~2–3 hours || Hexarelin | Very High | Moderate | Moderate | Moderate | Significant (7–14 days) | ~1.5 hours || Sermorelin | Moderate | None | None | None | None | ~10–20 minutes || MK-677 (oral) | High | None | Modest | Significant | None | ~24 hours |
- The 'Professional Assessment' column would note: for short-term GH studies prioritizing peak amplitude, hexarelin remains unmatched; for appetite-driven research, GHRP-6 is the standard; for long-duration protocols requiring consistent GH pulsatility without receptor desensitization or endocrine disruption, ipamorelin is the cleanest tool available.
- Our CJC1295 Ipamorelin 5MG 5MG blend combines the GHRH analog CJC-1295 (no DAC) with ipamorelin to leverage both pathways—researchers use this stack when they want supraphysiological GH output without the appetite or cortisol confounds.